Boehringer Ingelheim Strikes Third Deal of the Month with Bridge Biotherapeutics
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 7 (Table of Contents)
Published: 30 Jul-2019
DOI: 10.3833/pdr.v2019.i7.2443 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Joining Ofev® (nintedanib), Boehringer Ingelheim (BI) has gained another respiratory asset - BBT-877 - for the treatment of fibrosing interstitial lung diseasesfrom Bridge Biotherapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS